为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!

FG-4592,HIF-α脯氨酰羟化酶抑制剂, 低氧诱导因子脯氨酰羟化酶抑制剂

规格或纯度: ≥98%
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
F126178-10mg
10mg 现货 Stock Image
F126178-50mg
50mg 现货 Stock Image
F126178-250mg
250mg 现货 Stock Image
F126178-500mg
500mg 现货 Stock Image

基本描述

别名 罗沙司他
英文别名 FG-4592 (ASP1517)|NCGC00346527-01|NCGC00346527-07|N-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]glycine|Roxadustat|YOZBGTLTNGAVFU-UHFFFAOYSA-N|2-(4-hydroxy-1-Methyl-7-phenoxyisoquinoline-3-carboxaMido)acetic acid|Evrenzo|J-522733|3-chloro-2-hy
规格或纯度 ≥98%
英文名称 FG-4592
生化机理

FG-4592 is an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase currently in clinical development for the treatment of anemia. FG-4592 stabilizes the activities of HIF, a cytosolic transcription factor, leading to activation of the genes associated with erythropoiesis, including erythropoietin and enzymes involved in iron metabolism. A phase II clinical trial of FG-4592 has been competed in the treatment of chronic kidney disease.

储存温度 -20°C储存
运输条件 超低温冰袋运输
产品介绍

FG-4592是一种HIF α脯氨酰羟化酶抑制剂,并能稳定HIF-2,同时诱导EPO产生。

FG-4592 is an HIF α prolyl hydroxylase inhibitor, stabilizes HIF-2 and induces EPO production.

产品属性

ALogP 3.4

名称和标识符

IUPAC Name 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid
INCHI InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)
InChi Key YOZBGTLTNGAVFU-UHFFFAOYSA-N
Canonical SMILES CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3
Isomeric SMILES CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3
PubChem CID 11256664
分子量 352.34

化学和物理性质

溶解性 DMSO >70 mg/mL Water <1 mg/mL Ethanol <1 mg/mL

安全和危险性(GHS)

象形图
ghs07

Harmful

信号词 Warning
危险声明 H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
H302: Harmful if swallowed
H332: Harmful if inhaled
预防措施声明 P261,P305+P351+P338,P280,P302+P352,P321,P405,P501,P264,P271,P270,P304+P340,P403+P233,P362+P364,P330,P264+P265,P301+P317,P317,P337+P317,P332+P317,P319

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

相关文档

质检报告COA

请输入批号:


产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Bouchie A.  (2013)  First-in-class anemia drug takes aim at Amgen's dominion..  Nat Biotechnol,  31  (11):  (948-9).  [PMID:24213751]
2. Forristal CE, Levesque JP.  (2014)  Targeting the hypoxia-sensing pathway in clinical hematology..  Stem Cells Transl Med,  (2):  (135-40).  [PMID:24371328]